Genfit Not Fully Exiting NASH, Despite Terminating RESOLVE-IT
A fuller look at interim Phase III data shows no path forward to accelerated approval in NASH, company says. Genfit turns focus to developing elafibranor for PBC, as well as a NASH diagnostic.
You may also be interested in...
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and the firm has just launched its Remdac version of remdesivir.